{"pmid":32437933,"title":"Viral dynamics in asymptomatic patients with COVID-19.","text":["Viral dynamics in asymptomatic patients with COVID-19.","Data are limited on the viral load, viral shedding patterns and potential infectivity of asymptomatic patients (APs) with coronavirus disease 2019 (COVID-19). We included 31 adult patients who were virologically confirmed to have COVID-19 but were asymptomatic on admission. Among these 31 patients, 22 presented symptoms after admission and were defined as asymptomatic patients in incubation period (APIs); the other 9 patients remained asymptomatic during hospitalization and were defined as asymptomatic patients (APs). The cycle threshold (Ct) values of APs (39.0, IQR 37.5-39.5) was significantly higher than those of APIs (34.5, IQR 32.2-37.0), which indicated a lower viral load in APs, but the duration of viral shedding remained similar between the two groups (7 days IQR 5-14 vs. 8 days IQR 5-16). The study findings demonstrated that although they have a lower viral load, APs with COVID-19 still have certain period of viral shedding, which suggests the possibility of transmission during their asymptomatic period. Further longitudinal surveillance of these asymptomatic cases via virus nucleic acid tests are warranted.","Int J Infect Dis","Zhou, Rui","Li, Furong","Chen, Fengjuan","Liu, Huamin","Zheng, Jiazhen","Lei, Chunliang","Wu, Xianbo","32437933"],"abstract":["Data are limited on the viral load, viral shedding patterns and potential infectivity of asymptomatic patients (APs) with coronavirus disease 2019 (COVID-19). We included 31 adult patients who were virologically confirmed to have COVID-19 but were asymptomatic on admission. Among these 31 patients, 22 presented symptoms after admission and were defined as asymptomatic patients in incubation period (APIs); the other 9 patients remained asymptomatic during hospitalization and were defined as asymptomatic patients (APs). The cycle threshold (Ct) values of APs (39.0, IQR 37.5-39.5) was significantly higher than those of APIs (34.5, IQR 32.2-37.0), which indicated a lower viral load in APs, but the duration of viral shedding remained similar between the two groups (7 days IQR 5-14 vs. 8 days IQR 5-16). The study findings demonstrated that although they have a lower viral load, APs with COVID-19 still have certain period of viral shedding, which suggests the possibility of transmission during their asymptomatic period. Further longitudinal surveillance of these asymptomatic cases via virus nucleic acid tests are warranted."],"journal":"Int J Infect Dis","authors":["Zhou, Rui","Li, Furong","Chen, Fengjuan","Liu, Huamin","Zheng, Jiazhen","Lei, Chunliang","Wu, Xianbo"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437933","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.030","keywords":["covid-19","asymptomatic patients","viral load","viral shedding"],"topics":["Diagnosis"],"weight":1,"_version_":1667521393789501440,"score":9.490897,"similar":[{"pmid":32379191,"title":"Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan.","text":["Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan.","BACKGROUND: Information regarding viral shedding in children with coronavirus disease 2019 (COVID-19) was limited. This study aims to investigate the clinical and laboratory characteristics associated with viral shedding in children with mild COVID-19. METHODS: The clinical and laboratory information of 110 children with COVID-19 at Wuhan Children's Hospital, Wuhan, China, from January 30 to March 10, 2020, were analyzed retrospectively. RESULTS: The median age was 6 years old. The median period of viral shedding of COVID-19 was 15 days (interquartile range [IQR], 11-20 days) as measured from illness onset to discharge. This period was shorter in asymptomatic patients (26.4%) compared with symptomatic patients (73.6%) (11 days vs. 17 days). Multivariable regression analysis showed increased odds of symptomatic infection was associated with age <6 years (odds ratio [OR] 8.94, 95% confidence interval [CI]: 2.55-31.35; P = 0.001), hypersensitive C-reactive protein >3.0 mg/L (OR 4.89; 95% CI: 1.10-21.75; P = 0.037) and presenting pneumonia in chest radiologic findings (OR 8.45; 95% CI: 2.69-26.61; P < 0.001). Kaplan-Meier analysis displayed symptomatic infection (P < 0.001), fever (P = 0.006), pneumonia (P = 0.003) and lymphocyte counts <2.0 x 10/L (P = 0.008) in children with COVID-19 were associated with prolonged duration of viral shedding in children with COVID-19. CONCLUSION: Prolonged duration of viral shedding in children with COVID-19 was associated with symptomatic infection, fever, pneumonia and lymphocyte count =2.0 x 10/L. Monitoring of symptoms could help to know the viral shedding in children with COVID-19.","Pediatr Infect Dis J","Lu, Yingying","Li, Yi","Deng, Wenyue","Liu, Mingyang","He, Yuanzhi","Huang, Lingyue","Lv, Mengxue","Li, Jianxin","Du, Hao","32379191"],"abstract":["BACKGROUND: Information regarding viral shedding in children with coronavirus disease 2019 (COVID-19) was limited. This study aims to investigate the clinical and laboratory characteristics associated with viral shedding in children with mild COVID-19. METHODS: The clinical and laboratory information of 110 children with COVID-19 at Wuhan Children's Hospital, Wuhan, China, from January 30 to March 10, 2020, were analyzed retrospectively. RESULTS: The median age was 6 years old. The median period of viral shedding of COVID-19 was 15 days (interquartile range [IQR], 11-20 days) as measured from illness onset to discharge. This period was shorter in asymptomatic patients (26.4%) compared with symptomatic patients (73.6%) (11 days vs. 17 days). Multivariable regression analysis showed increased odds of symptomatic infection was associated with age <6 years (odds ratio [OR] 8.94, 95% confidence interval [CI]: 2.55-31.35; P = 0.001), hypersensitive C-reactive protein >3.0 mg/L (OR 4.89; 95% CI: 1.10-21.75; P = 0.037) and presenting pneumonia in chest radiologic findings (OR 8.45; 95% CI: 2.69-26.61; P < 0.001). Kaplan-Meier analysis displayed symptomatic infection (P < 0.001), fever (P = 0.006), pneumonia (P = 0.003) and lymphocyte counts <2.0 x 10/L (P = 0.008) in children with COVID-19 were associated with prolonged duration of viral shedding in children with COVID-19. CONCLUSION: Prolonged duration of viral shedding in children with COVID-19 was associated with symptomatic infection, fever, pneumonia and lymphocyte count =2.0 x 10/L. Monitoring of symptoms could help to know the viral shedding in children with COVID-19."],"journal":"Pediatr Infect Dis J","authors":["Lu, Yingying","Li, Yi","Deng, Wenyue","Liu, Mingyang","He, Yuanzhi","Huang, Lingyue","Lv, Mengxue","Li, Jianxin","Du, Hao"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379191","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1097/INF.0000000000002729","locations":["Wuhan","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666597097407774721,"score":265.66238},{"pmid":32445580,"title":"Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China.","text":["Chronological Changes of Viral Shedding in Adult Inpatients with COVID-19 in Wuhan, China.","BACKGROUND: In December 2019, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan. Epidemiological and clinical characteristics of patients with COVID-19 have been reported, but the relationships between laboratory features and viral load has not been comprehensively described. METHODS: Adult inpatients (>/=18 years old) with COVID-19 who underwent multiple (>/= 5 times) nucleic acid tests with nasal and pharyngeal swabs were recruited from Renmin Hospital of Wuhan University, including general patients (n=70), severe patients (n=195) and critical patients (n=43). Laboratory data, demographic and clinical data were extracted from electronic medical records. The fitted polynomial curve was used to explore the association between serial viral loads and illness severity. RESULTS: Viral load of SARS-CoV-2 peaked within the first few days (2-4 days) after admission, then decreased rapidly along with virus rebound under treatment. Critical patients had the highest viral loads, in contrast to the general patients showing the lowest viral loads. The viral loads were higher in sputum compared with nasal and pharyngeal swab (p=0.026). The positive rate of respiratory tract samples was significantly higher than that of gastrointestinal tract samples (p<0.001). The SARS-CoV-2 viral load was negatively correlated with portion parameters of blood routine and lymphocyte subsets, and was positively associated with laboratory features of cardiovascular system. CONCLUSIONS: The serial viral loads of patients revealed whole viral shedding during hospitalization and the resurgence of virus during the treatment, which could be used for early warning of illness severity, thus improve antiviral interventions.","Clin Infect Dis","Huang, Jing-Tao","Ran, Ruo-Xi","Lv, Zhi-Hua","Feng, Li-Na","Ran, Chen-Yang","Tong, Yong-Qing","Li, Dong","Su, Han-Wen","Zhu, Cheng-Liang","Qiu, Shi-Li","Yang, Jie","Xiao, Meng-Yao","Liu, Ming-Jun","Yang, Yu-Ting","Liu, Song-Mei","Li, Yan","32445580"],"abstract":["BACKGROUND: In December 2019, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out in Wuhan. Epidemiological and clinical characteristics of patients with COVID-19 have been reported, but the relationships between laboratory features and viral load has not been comprehensively described. METHODS: Adult inpatients (>/=18 years old) with COVID-19 who underwent multiple (>/= 5 times) nucleic acid tests with nasal and pharyngeal swabs were recruited from Renmin Hospital of Wuhan University, including general patients (n=70), severe patients (n=195) and critical patients (n=43). Laboratory data, demographic and clinical data were extracted from electronic medical records. The fitted polynomial curve was used to explore the association between serial viral loads and illness severity. RESULTS: Viral load of SARS-CoV-2 peaked within the first few days (2-4 days) after admission, then decreased rapidly along with virus rebound under treatment. Critical patients had the highest viral loads, in contrast to the general patients showing the lowest viral loads. The viral loads were higher in sputum compared with nasal and pharyngeal swab (p=0.026). The positive rate of respiratory tract samples was significantly higher than that of gastrointestinal tract samples (p<0.001). The SARS-CoV-2 viral load was negatively correlated with portion parameters of blood routine and lymphocyte subsets, and was positively associated with laboratory features of cardiovascular system. CONCLUSIONS: The serial viral loads of patients revealed whole viral shedding during hospitalization and the resurgence of virus during the treatment, which could be used for early warning of illness severity, thus improve antiviral interventions."],"journal":"Clin Infect Dis","authors":["Huang, Jing-Tao","Ran, Ruo-Xi","Lv, Zhi-Hua","Feng, Li-Na","Ran, Chen-Yang","Tong, Yong-Qing","Li, Dong","Su, Han-Wen","Zhu, Cheng-Liang","Qiu, Shi-Li","Yang, Jie","Xiao, Meng-Yao","Liu, Ming-Jun","Yang, Yu-Ting","Liu, Song-Mei","Li, Yan"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445580","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/cid/ciaa631","keywords":["coronavirus disease 2019","laboratory features","viral load","viral shedding"],"locations":["Wuhan","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667600475800731648,"score":263.38275},{"pmid":32270479,"title":"Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia.","text":["Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia.","OBJECTIVE: To study chest CT images and clinical characteristics of COVID-19 pneumonia in pregnant patients to examine any correlation. METHODS: Between December 31, 2019 and March 7, 2020, 23 hospitalized pregnant patients with confirmed COVID-19 were enrolled in the study. Clinical presentations were collected retrospectively from records, including laboratory testing, chest CT imaging, and symptoms. Descriptive analysis and correlation of patients' clinical and CT characteristics were performed. Laboratory results from time of first admission and CT absorption (defined as reduction in lesion area, decrease in density, and absorption of some solid components) were compared between symptomatic and asymptomatic patients. RESULTS: Fifteen (65.2%) patients were asymptomatic with patchy ground-glass opacity in a single lung lobe. Eight (34.8%) patients were symptomatic with multiple patchy ground-glass shadows, consolidation, and fibrous stripes. Differences in lymphocyte percentage and neutrophil granulocyte rate between first admission and CT absorption were significant (P<0.001). Median absorption time was shorter in the asymptomatic group compared with the symptomatic group (5 vs 10 days; P<0.001). Median hospitalization time between asymptomatic and symptomatic patients was 14 vs 25.5 days; P>0.001. Median absorption time and length of hospitalization for all patients was 6 days (IQR 5-8) and 17 days (IQR 13-25), respectively. CONCLUSION: Radiological findings and clinical characteristics in pregnant women with COVID-19 were similar to those of non-pregnant women with COVID-19. Median absorption time and length of hospitalization in asymptomatic patients were significantly shorter than in symptomatic patients. Lymphocyte percentage and neutrophil granulocyte rate may be used as laboratory indicators of CT absorption.","Int J Gynaecol Obstet","Wu, Xiaoqing","Sun, Ruihong","Chen, Jianpu","Xie, Yuanliang","Zhang, Shutong","Wang, Xiang","32270479"],"abstract":["OBJECTIVE: To study chest CT images and clinical characteristics of COVID-19 pneumonia in pregnant patients to examine any correlation. METHODS: Between December 31, 2019 and March 7, 2020, 23 hospitalized pregnant patients with confirmed COVID-19 were enrolled in the study. Clinical presentations were collected retrospectively from records, including laboratory testing, chest CT imaging, and symptoms. Descriptive analysis and correlation of patients' clinical and CT characteristics were performed. Laboratory results from time of first admission and CT absorption (defined as reduction in lesion area, decrease in density, and absorption of some solid components) were compared between symptomatic and asymptomatic patients. RESULTS: Fifteen (65.2%) patients were asymptomatic with patchy ground-glass opacity in a single lung lobe. Eight (34.8%) patients were symptomatic with multiple patchy ground-glass shadows, consolidation, and fibrous stripes. Differences in lymphocyte percentage and neutrophil granulocyte rate between first admission and CT absorption were significant (P<0.001). Median absorption time was shorter in the asymptomatic group compared with the symptomatic group (5 vs 10 days; P<0.001). Median hospitalization time between asymptomatic and symptomatic patients was 14 vs 25.5 days; P>0.001. Median absorption time and length of hospitalization for all patients was 6 days (IQR 5-8) and 17 days (IQR 13-25), respectively. CONCLUSION: Radiological findings and clinical characteristics in pregnant women with COVID-19 were similar to those of non-pregnant women with COVID-19. Median absorption time and length of hospitalization in asymptomatic patients were significantly shorter than in symptomatic patients. Lymphocyte percentage and neutrophil granulocyte rate may be used as laboratory indicators of CT absorption."],"journal":"Int J Gynaecol Obstet","authors":["Wu, Xiaoqing","Sun, Ruihong","Chen, Jianpu","Xie, Yuanliang","Zhang, Shutong","Wang, Xiang"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270479","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1002/ijgo.13165","keywords":["covid-19","ct scan","pneumonia","pregnancy"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491851898880,"score":263.31317},{"pmid":32425636,"pmcid":"PMC7231495","title":"Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: A retrospective cohort study.","text":["Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: A retrospective cohort study.","Objectives: To investigate factors associated with the duration of viral shedding in patients with COVID-19 outside of Wuhan. Methods: In this retrospective cohort study, patients with laboratory-confirmed COVID-19 in Changsha, China were included. Clinical characteristics, laboratory findings, treatment and outcome were retrieved. Univariable and multivariable analysis were performed to explore potential factors. Results: Totally 147 patients with COVID-19 were included. The median duration of viral shedding (the number of days from symptoms onset till the successive negative detection of SARS-CoV-2 RNA) was 17 days (interquartile range [IQR], 12 to 21). Multivariable Logistic regression analysis indicated that the highest temperature at admission (odds ratio [OR], 5.200; 95% confidence interval [CI]: 1.190-22.726; p = 0.028) and time from symptom onset to admission (OR, 1.740; 95% CI: 1.296-2.337; p < 0.001) and hospital length of stay (OR, 1.604; 95% CI: 1.262-2.040; p < 0.001) were risk factors for prolonged duration of viral shedding. Conclusions: This is the study with relatively large sample size that mainly focused on the duration of viral shedding and relevant factors in patients with COVID-19 outside of Wuhan, China. Potential risk factors were identified and should be taken into consideration for the strategy of quarantine of infected patients.","Int J Infect Dis","Qi, Lin","Yang, Yong","Jiang, Dixuan","Tu, Chao","Wan, Lu","Chen, Xiangyu","Li, Zhihong","32425636"],"abstract":["Objectives: To investigate factors associated with the duration of viral shedding in patients with COVID-19 outside of Wuhan. Methods: In this retrospective cohort study, patients with laboratory-confirmed COVID-19 in Changsha, China were included. Clinical characteristics, laboratory findings, treatment and outcome were retrieved. Univariable and multivariable analysis were performed to explore potential factors. Results: Totally 147 patients with COVID-19 were included. The median duration of viral shedding (the number of days from symptoms onset till the successive negative detection of SARS-CoV-2 RNA) was 17 days (interquartile range [IQR], 12 to 21). Multivariable Logistic regression analysis indicated that the highest temperature at admission (odds ratio [OR], 5.200; 95% confidence interval [CI]: 1.190-22.726; p = 0.028) and time from symptom onset to admission (OR, 1.740; 95% CI: 1.296-2.337; p < 0.001) and hospital length of stay (OR, 1.604; 95% CI: 1.262-2.040; p < 0.001) were risk factors for prolonged duration of viral shedding. Conclusions: This is the study with relatively large sample size that mainly focused on the duration of viral shedding and relevant factors in patients with COVID-19 outside of Wuhan, China. Potential risk factors were identified and should be taken into consideration for the strategy of quarantine of infected patients."],"journal":"Int J Infect Dis","authors":["Qi, Lin","Yang, Yong","Jiang, Dixuan","Tu, Chao","Wan, Lu","Chen, Xiangyu","Li, Zhihong"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425636","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.045","keywords":["2019 novel coronavirus disease (covid-19)","changsha","risk factor","viral shedding"],"locations":["Wuhan","Changsha","China","Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667352728914886657,"score":263.23224},{"pmid":32492211,"title":"Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.","text":["Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.","BACKGROUND: Prolonged viral shedding may pose a threat to the control of coronavirus disease 2019 (COVID-19), and data on the duration of SARS-CoV-2 shedding are still limited, with the associated factors being unknown. METHODS: All adult patients with laboratory-confirmed COVID-19 were included in this retrospective cross-sectional study in two designated hospitals during 21 January 2020-16 March 2020 in Anhui, China. In all patients, data on the duration of SARS-CoV-2 RNA shedding were analyzed by reviewing all RNA detection results during hospitalization. Additionally, demographic, clinical, treatment, laboratory and outcome data were also collected from electronic medical records. Factors associated with prolonged viral shedding were analyzed with the Cox proportional hazards model. RESULTS: Among 181 patients, the mean age was 44.3+/-13.2 years, and 55.2% were male. The median duration of viral shedding from illness onset was 18.0 days (IQR 15.0-24.0). Prolonged viral shedding was associated with longer hospital stays (P<0.001) and higher medical costs (P<0.001). The severity of COVID-19 had nothing to do with prolonged shedding. Moreover, the median time from onset to antiviral treatment initiation was 5.0 days (IQR 3.0-7.0). Delayed antiviral treatment (HR 0.976 [95% CI, 0.962-0.990]) and lopinavir/ritonavir + IFN-alpha combination therapy as the initial antiviral treatment (HR 1.649 [95% CI, 1.162-2.339]) were independent factors associated with prolonged SARS-CoV-2 RNA shedding. CONCLUSIONS: SARS-CoV-2 showed prolonged viral shedding, causing increased hospital stays and medical costs. Early initiation of lopinavir/ritonavir + IFN-alpha combination therapy may help shorten the duration of SARS-CoV-2 shedding. This article is protected by copyright. All rights reserved.","J Med Virol","Zuo, Yan","Liu, Yunlei","Zhong, Qi","Zhang, Ke","Xu, Yuanhong","Wang, Zhongxin","32492211"],"abstract":["BACKGROUND: Prolonged viral shedding may pose a threat to the control of coronavirus disease 2019 (COVID-19), and data on the duration of SARS-CoV-2 shedding are still limited, with the associated factors being unknown. METHODS: All adult patients with laboratory-confirmed COVID-19 were included in this retrospective cross-sectional study in two designated hospitals during 21 January 2020-16 March 2020 in Anhui, China. In all patients, data on the duration of SARS-CoV-2 RNA shedding were analyzed by reviewing all RNA detection results during hospitalization. Additionally, demographic, clinical, treatment, laboratory and outcome data were also collected from electronic medical records. Factors associated with prolonged viral shedding were analyzed with the Cox proportional hazards model. RESULTS: Among 181 patients, the mean age was 44.3+/-13.2 years, and 55.2% were male. The median duration of viral shedding from illness onset was 18.0 days (IQR 15.0-24.0). Prolonged viral shedding was associated with longer hospital stays (P<0.001) and higher medical costs (P<0.001). The severity of COVID-19 had nothing to do with prolonged shedding. Moreover, the median time from onset to antiviral treatment initiation was 5.0 days (IQR 3.0-7.0). Delayed antiviral treatment (HR 0.976 [95% CI, 0.962-0.990]) and lopinavir/ritonavir + IFN-alpha combination therapy as the initial antiviral treatment (HR 1.649 [95% CI, 1.162-2.339]) were independent factors associated with prolonged SARS-CoV-2 RNA shedding. CONCLUSIONS: SARS-CoV-2 showed prolonged viral shedding, causing increased hospital stays and medical costs. Early initiation of lopinavir/ritonavir + IFN-alpha combination therapy may help shorten the duration of SARS-CoV-2 shedding. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zuo, Yan","Liu, Yunlei","Zhong, Qi","Zhang, Ke","Xu, Yuanhong","Wang, Zhongxin"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492211","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26127","keywords":["covid-19","associated factors","outcomes","treatment","viral shedding"],"locations":["Anhui","China","Anhui","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1668892169361948672,"score":261.15134}]}